Tavapadon

DB14899InvestigationalSmall molecule

Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects).

Mechanism: Pharmacologically active on Dopamine receptor D1 and Dopamine receptor D5
Curator reviewed
Formula / weight: C₁₉H₁₆F₃N₃O₃ · 391.35 g/mol (avg)
Also known as: PF-06649751

Resolves to

Compound

UNIIPT4P8MJP8LCAS1643489-24-0ChEMBLCHEMBL3697617ChEBI755713PubChem86764100

Structure

InChIKeyAKQXQLUNFKDZBN-UHFFFAOYSA-NSMILESCN1C(=O)NC(=O)C(C)=C1C1=C(C)C=C(OC2=NC=CC=C2C(F)(F)F)C=C1

Targets

P21728DRD1P21918DRD5

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

13Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tavapadon, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account